A method of expanding and maintaining human embryonic stem cells (ESCs) in an undifferentiated state by culturing the ESCs in a suspension culture under culturing conditions devoid of substrate adherence is provided. Also provided are a method of deriving ESC lines in the suspension culture and methods of generating lineage-specific cells from ESCs which were expanded in the suspension culture of the present invention.

Provided herein are, inter alia, methods for preparing a liquid cell culture media that has lesser lot-to-lot analytical variation, increased performance, and has lesser metal ion concentrations compared to a liquid media prepared by traditional methods. Such liquid media may be used for culturing cells, including but not limited to, recombinant cells.

By using an additive for culturing animal cells that contains an amino acid or glucose, or an amino acid and glucose; or a medium for culturing animal cells that contains an amino acid or glucose, or an amino acid and glucose in addition to a medium component; or a method for culturing animal cells that includes culturing the animal cells using the aforementioned medium, or adding the aforementioned additive to a culture, the proliferation ability of animal cells can be improved particularly when the animal cells are cultured using a serum-free medium or a low albumin medium.

The present invention provides a composition having a metabolism-improving action, which comprises a supernatant of brown adipocytes or a purified product thereof. The present invention also provides a method of preparing the supernatant without using a culture solution comprising a high concentration of glucose. The present invention also provides a method of producing brown adipocytes using pluripotent stem cells, which are useful for preparing the supernatant of brown adipocytes. The present invention has succeeded in obtaining a supernatant having a metabolism-improving action from brown adipocytes. It was also possible to obtain the supernatant without using a culture solution comprising a high concentration of glucose. The present invention has also succeeded in producing brown adipocytes from pluripotent stem cells using a feeder-free culture system without adding a cytokine cocktail or the like. The brown adipocyte supernatant of the present invention is expected to be applied to the development of therapeutic agents and cosmetic products for glucose metabolism diseases.

The present invention includes compositions and method of generating human corneal epithelial stem cells, a human corneal epithelial stem cell supernatant, or both, the method comprising: wetting and mincing a corneal epithelial sample in a media, drying the minced corneal epithelial sample until sample edges are adhered to a substrate, adding a growth media comprising fetal bovine serum or human serum to the minced corneal epithelial sample without dislodging the minced corneal epithelial sample from the substrate with an amount of media that permits at least a portion of the minced corneal epithelial sample to be in contact with air, culturing the minced corneal epithelial sample for one or more days, changing the growth media to a media comprising a human corneal growth supplement (HCGS) with no fetal bovine serum, culturing the cells to grow human corneal epithelial stem cells, a human corneal epithelial stem cell supernatant, or both.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Disclosed are methods for the purification of a recombinant AAV (rAAV) particle from a mammalian host cell culture. The disclosure further provides a pharmaceutical composition produced by the methods of the disclosure, pharmaceutical compositions and method of using the pharmaceutical compositions described herein for the treatment of disease.

Disclosed herein are methods and compositions comprising placental adherent stromal cells for treating viral infections and sequelae thereof.

The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.